PHASE II STUDY OF OFATUMUMAB PLUS IFOSFAMIDE, CARBOPLATIN, ETOPOSIDE (ICE) OR DEXAMETHASONE, CYTARABINE, CISPLATIN (DHAP) CHEMOTHERAPY REGIMEN IN RELAPSED/ REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (DLBCL):